<?xml version="1.0" encoding="UTF-8"?>
<p>To assess the impact of 
 <italic>L</italic>. 
 <italic>paracasei</italic> CNCM I-1518 oral administration on resistance toward influenza infection, we first focused on the health status evolution of mice receiving either 
 <italic>L</italic>. 
 <italic>paracasei</italic> or control (Phosphate Saline Buffer: PBS) 7 days prior to viral infection. Mice were infected intranasally with influenza A H3N2 variant virus at day 0 and followed up to 10 days after viral infection (
 <xref ref-type="fig" rid="pone.0184976.g001">Fig 1A</xref>).
</p>
